In vitro evaluation of tigecycline against multidrug-resistant bacteria in Niger: Resistance trends and clinical implications | ||||
| Microbes and Infectious Diseases | ||||
| Articles in Press, Accepted Manuscript, Available Online from 05 June 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mid.2025.366345.2615 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Massir Issoufou Noma   1, 2; Abdourahamane Yacouba 3, 4; Ounoussa Tapha 3; Harouna Moussa3; Lamine Mahaman Moustapha 1; Souleymane Brah4, 5; Mahamadou Doutchi2, 6
| ||||
| 1Laboratoire de Recherche Clinique et Système de Santé, Université André Salifou, Zinder, Niger | ||||
| 2Département de Médecine, Faculté des Sciences de Santé, Université André Salifou, Zinder, Niger | ||||
| 3Laboratoire National de Reference sur la Resistance aux Antimicrobiens, Hôpital National Amirou Boubacar Diallo, Niamey, Niger | ||||
| 4Département de Médecine, Faculté des Sciences de santé, Université Abdou Moumouni, Niamey, Niger | ||||
| 5Département de Médicine, Hôpital National Amirou Boubacar Diallo, Niamey, Niger | ||||
| 6Département de Médecine, Hôpital National de Zinder, Zinder, Niger | ||||
| Abstract | ||||
| Background: Multidrug-resistant (MDR) bacteria significantly threaten public health globally. In recent years, new molecules such as tigecycline have been introduced to combat these MDR bacteria. This study aimed to assess the in vitro activity of tigecycline against MDR bacteria in Niger. Methods: A cross-sectional study was conducted at the National Reference Laboratory for Antimicrobial Resistance (NRL-AMR) on multidrug-resistant (MDR) isolates from pathological samples. The isolates were tested in vitro with tigecycline using the agar diffusion method (Kirby–Bauer) according to the EUCAST 2024 recommendations. Results: A total of 312 MDR bacterial isolates were included: 198 ESBL, 14 CRAB, 27 CRPA, 26 MRSA, and 47 CRE. The in vitro test with tigecycline showed a sensitivity of 83.01% with a resistance rate of 16.99%. A resistance rate of 100% was found in CRPA, followed by CRAB (35.71%), CRE (14.90%), and ESBL (7.09%), with a sensitivity rate of 100% for MRSA isolates. Conclusion: Although tigecycline has shown good results against clinical MRSA, ESBL, and CRE isolates, the emergence of tigecycline-resistant isolates has been observed, which might seem alarming. We suggest exploring a combination therapy of tigecycline with cefiderecol or colistin as a potential treatment option against CRAB and CRPA infections in Niger. | ||||
| Keywords | ||||
| Tigecycline; Anti-Bacterial Agents; Drug-resistant; Niger | ||||
|
Statistics Article View: 135 |
||||
